Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Retro Biosciences, valued at $1.8 billion, is advancing a clinical-stage oral therapeutic targeting protein aggregate clearance in Alzheimer's disease pathology, with preliminary safety data supporting continued human testing. The transition from preclinical research to early-stage clinical trials represents a materialization of mechanistic longevity approaches into testable interventions.
Omega-3 polyunsaturated fatty acids reduce cellular senescence in kidney tissue through FFAR4 activation, restoring filtration function and reducing fibrosis in aged mice and disease models. This mechanism explains previously mixed clinical findings and identifies a specific pathway relevant to chronic kidney disease progression.
ProHealth's BPC-157 Ultra Probiotic combines a prebiotic, direct butyrate source, butyrate-producing probiotic, and the peptide BPC-157 in a fully disclosed formulation with third-party verification. The product targets butyrate production and gut barrier function, though human clinical evidence for BPC-157 remains limited to animal models and it carries regulatory uncertainty.
Resbiotic has launched a direct-to-consumer microbiome test using shotgun metagenomics sequencing, offering personalized reports on microbial diversity, gut inflammation markers, intestinal permeability, and keystone bacterial strains. The test integrates with the company's probiotic formulas, enabling consumers to track microbiome changes over 60- to 90-day intervals and adjust supplementation based on longitudinal data.
ProHealth introduced Essentials NMN 500, a 500 mg nicotinamide mononucleotide supplement using an amorphous formulation claimed to enhance bioavailability, priced at $24.95 for 30 capsules. Published research supports that NMN supplementation raises blood NAD+ levels within the 250-1,200 mg dose range, though direct clinical comparison data between formulation types remains limited.
A predictive equation successfully identifies cats with reduced kidney function using non-invasive markers, offering an alternative to standard clinical assessment. Early detection of renal decline in feline populations could extend healthspan through timely intervention before symptomatic disease emerges.
Elevated serum uric acid independently predicts progression to cardiometabolic disease and multimorbidity, with gout serving as a clinical marker of this systemic risk. This relationship persists across metabolic phenotypes, suggesting uric acid operates as a metabolic signal warranting earlier intervention than current clinical thresholds recognize.
Omega-3 polyunsaturated fatty acids reduce kidney aging and fibrosis through a receptor called FFAR4, which activates cellular regeneration pathways in tubular cells. FFAR4 expression declines with age and in chronic kidney disease patients, and restoring its signaling mitigates senescence and fibrotic progression.
Scribe Therapeutics presented preclinical data on epigenetic gene silencing that reduces off-target effects by 10- to 100-fold while maintaining durable therapeutic effects. Their lead program targets PCSK9 for cholesterol reduction, with nonhuman primate data showing sustained effects lasting nearly 18 months after a single treatment—a shift from permanent DNA editing toward controlled, reversible intervention.
Codexis has advanced enzymatic RNA manufacturing with precise stereochemical control and full-length siRNA synthesis capability, while reducing environmental impact by over 50% through aqueous processing and minimal organic solvent use. This development accelerates the scalability and sustainability of RNA therapeutics, a critical class of drugs targeting aging-related diseases and tissue regeneration.
Scribe Therapeutics has received regulatory approval to begin human testing of STX-1150, an epigenetic therapy designed to silence PCSK9 and lower LDL cholesterol through a single mRNA-based treatment delivered via lipid nanoparticle to the liver. This represents the first clinical evaluation of a reversible epigenetic silencing approach to cholesterol management, offering potential for sustained LDL reduction without permanent genomic alteration.
Aging reduces vaccine efficacy through two interconnected mechanisms: disruption of gut microbial composition and dysregulated mTOR signaling. Restoring microbial diversity and moderating mTOR activity represent tractable targets for improving immune protection in older adults.